Catalase-Integrated Hyaluronic Acid as Nanocarriers for Enhanced Photodynamic Therapy in Solid Tumor
Open accessAbstract
Photodynamic therapy (PDT) as a treatment method has many advantages such as minimal invasiveness, repeatable dosage, and low systemic toxicity. Issues with conventional PDT agents include the limited availability of endogenous oxygen and difficulty in accumulation at the tumor site, which has hindered the successful treatment of tumors. Herein, we developed catalase-encapsulated hyaluronic-acid-based nanoparticles loaded with adamantane-modified photosensitizer for enhanced PDT of solid tumors. Chlorin e6 (Ce6) as the photosensitizer was modified with adamantane to yield adamantane-modified Ce6 (aCe6). The obtained nanosystem (HA-CAT@aCe6) could target overly expressed CD44 receptors on cancer cells, supplying oxygen by converting endogenous hydrogen peroxide (H 2 O 2 ) to oxygen, and improving PDT efficacy upon light irradiation. HA-CAT@aCe6 nanoparticles showed high colloidal stability and monodispersity in aqueous solution. The uptake and targeting property of HA-CAT@aCe6 were demonstrated by confocal microscopy and flow cytometry in the MDA-MB-231 cell line possessing overly expressed CD44 receptors. The encapsulated catalase was able to decompose the endogenous H 2 O 2 to generate O 2 in situ for relieving hypoxia in cells incubated under hypoxic conditions. Cell viability assays indicated that HA-CAT@aCe6 possessed minimal cytotoxicity in the dark, while presenting high cellular toxicity under 660 nm light irradiation at normoxic conditions. As a result of the catalase capability in relieving hypoxia, HA-CAT@aCe6 also exhibited high cellular cytotoxicity under hypoxic condition. In vivo experiments revealed selective tumor accumulation of HA-CAT@aCe6 in MDA-MB-231 tumor bearing nude mice. Significant tumor regression was observed after intravenous injection of HA-CAT@aCe6 under light irradiation in comparison to the control system without loading catalase. Thus, HA-CAT@aCe6 demonstrated a great potential in overcoming hypoxia for targeted PDT.
AI snapshot
Written from the paper’s full text.
TL;DR
The paper reports HA-CAT@aCe6 nanoparticles that combine CD44-targeting hyaluronic acid, catalase, and adamantane-modified chlorin e6 for photodynamic therapy. The system relieves tumor hypoxia by converting endogenous H₂O₂ to O₂ and improves PDT efficacy in MDA-MB-231 cells and tumor-bearing mice.
Key findings
- HA-CAT@aCe6 NPs had a hydrodynamic diameter of 233.6 nm and zeta potential of −13.6 mV; aCe6 entrapment efficiency was 80.1%, loading efficiency was 2.0% (w/w), and final aCe6 concentration was 9.7 µM.
- HA-CAT retained more than 90% catalase activity after 2 h with proteinase K, whereas free catalase activity dropped to near zero within 2 h; however, HA-CAT activity was estimated at 15.3% of free catalase.
- In MDA-MB-231 cells, HA-CAT@aCe6 showed minimal dark cytotoxicity (>90% viability) and IC₅₀ values of 1.4 µM under normoxia and 0.72 µM under hypoxia, compared with HA@aCe6 IC₅₀ values of 2.2 µM and 4.8 µM, respectively.
- In vivo, HA-CAT@aCe6 plus light produced the greatest tumor growth inhibition, lowest tumor mass, and most severe necrosis by H&E/TUNEL among five treatment groups, with no major systemic toxicity observed.
Methods
- HA-CD was conjugated to catalase via EDC/HOBt coupling, and aCe6 was loaded by supramolecular inclusion between adamantane and β-cyclodextrin; the HA-CD:catalase mass ratio of 3:1 was selected for further study.
- Characterization included TEM, DLS, zeta potential, SDS-PAGE, absorbance, BCA protein assay, Amplex Red catalase assay, Góth method, SOSG singlet oxygen detection, confocal microscopy, and flow cytometry.
- In vitro studies used CD44⁺ MDA-MB-231 and CD44⁻ MCF-7 cells under normoxia (21% O₂) and hypoxia (1% O₂); in vivo studies used MDA-MB-231 tumor-bearing nude mice, five groups of five mice, intravenous injection, and 660 nm light irradiation (50 mW/cm² for 30 min), with tumor volume monitored for 14 days.
Limitations
- The paper does not state a dedicated limitations section.
- Evident from the text: catalase activity in HA-CAT was only 15.3% of free catalase, which may constrain oxygen generation despite retained stability.
- Evident from the text: efficacy and targeting were tested mainly in MDA-MB-231 breast cancer cells and one MDA-MB-231 tumor model, with no long-term survival or chronic toxicity assessment beyond 14-day tumor growth and organ histology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 31 cited sources checked · 0 supported · 0 flagged
- Findingown data
After conjugation of HA-CD onto catalase to form HA-CAT, a trailing band was observed in SDS-PAGE, resulting from increased molecular weight of HA-CAT.
“After the conjugation of HA-CD onto catalase to form HA-CAT, a trailing band was observed in the SDS-PAGE lane (lane 3), which was a result of the increased molecular weight of HA-CAT.”
Quote in the paperSubstantial claim - Findingown data
TEM images show a spherical morphology for both HA-CAT and HA-CAT@aCe6 NPs.
“Transmission electron microscopy (TEM) images show a spherical morphology for both HA-CAT and HA-CAT@aCe6 NPs (Figure 1a,b).”
Quote in the paperNot a substantial claim - Findingown data
Presence of characteristic absorbance bands of aCe6 at around 400 nm and 660 nm with aggregation-induced blue shift confirmed successful entrapment of aCe6 in HA-CAT@aCe6 NPs.
“After the photosensitizer loading, the presence of characteristic absorbance bands of aCe6 at around 400 nm and 660 nm with the aggregation-induced blue shift confirmed the successful entrapment of aCe6 in HA-CAT@aCe6 NPs (Figure 1f).”
Quote in the paperSubstantial claim - Findingown data
Vertical gel electrophoresis verified successful synthesis of HA-CAT.
“Vertical gel electrophoresis was used to verify the successful synthesis of HA-CAT (Figure 1e).”
Quote in the paperSubstantial claim - Findingown data
The mass amount of HA-CD to catalase in HA-CAT was approximately 1.4:1.
“The mass amount of HA-CD to catalase was approximately 1.4:1 as determined by the subtraction of the catalase mass (measured by the BCA protein assay) from the known dried mass of HA-CAT.”
Quote in the paperNot a substantial claim
- Findingown data
The final concentration of aCe6 was 9.7 μM.
“The final concentration of aCe6 was determined to be 9.7 µM by referencing to the standard calibration curve of aCe6 (Figure S6).”
Quote in the paperNot a substantial claim - Findingown data
Photosensitizer loading efficiency was 2.0% (w/w) with reference to the mass of HA-CAT.
“The photosensitizer loading efficiency was found to be 2.0 % (w/w), with reference to the mass of HA-CAT.”
Quote in the paperNot a substantial claim - Findingown data
For the same concentration of catalase, the activity of HA-CAT was 15.3% of free catalase.
“For the same concentration of catalase in HA-CAT and free catalase, the activity of HA-CAT was estimated to be 15.3% of free catalase, determined using the Amplex Red Catalase Kit.”
Quote in the paperSubstantial claim - Findingown data
Low molecular weight HA (8-15 kDa) was conjugated to beta-cyclodextrin to produce HA-CD with a conjugation degree of 6.56%.
“Low molecular weight HA (8 -15 kDa) was conjugated to β-cyclodextrin to produce HA-CD with a conjugation degree of 6.56%.”
Quote in the paperSubstantial claim - Findingown data
Entrapment efficiency of aCe6 by HA-CAT NPs at catalase concentration 40 μg/mL was 80.1%.
“The entrapment efficiency of aCe6 by HA-CAT NPs ([catalase] = 40 µg/mL) was found to be 80.1 %.”
Quote in the paperNot a substantial claim - Findingown data
Hypoxia could be relieved using either HA-CAT or HA-CAT@aCe6 NPs upon light irradiation under both normoxic and hypoxic conditions.
“The results showed that hypoxia could be relieved using either HA-CAT or HA-CAT@aCe6 NPs upon light irradiation under both normoxic and hypoxic conditions.”
Quote in the paperSubstantial claim - Findingown data
High green fluorescence intensity was observed from hypoxic cells, indicating presence of HIF-1α proteins in the cells.
“As shown in Figure 2c, high green fluorescence intensity was observed from the hypoxic cells, indicating the presence of HIF-1α proteins in the cells.”
Quote in the paperSubstantial claim - Findingown data
Confocal images of MDA-MB-231 cells showed brighter fluorescence from loaded photosensitizer at longer incubation period, showing time-dependent uptake of HA-CAT@aCe6 under both normoxic and hypoxic conditions.
“Under both incubation conditions, the confocal images of MDA-MB-231 cells showed brighter fluorescence resulted from the loaded photosensitizer at longer incubation period, showing time-dependent uptake of HA-CAT@aCe6.”
Quote in the paperNot a substantial claim - Findingown data
Fluorescence from MDA-MB-231 cells was brighter than that of MCF-7 cells at 2 h and 4 h after incubation with HA-CAT@aCe6 NPs.
“Following the incubation of HA-CAT@aCe6 NPs with CD44 + MDA-MB-231 and CD44 -MCF-7 cells respectively (Figure S9b), the fluorescence from MDA-MB-231 cells was brighter as compared to that of MCF-7 cells at incubation times of both 2 h and 4 h.”
Quote in the paperSubstantial claim - Findingown data
CD44+ MDA-MB-231 cells expressed a greater amount of CD44 receptors than CD44- MCF-7 cells.
“The levels of CD44 receptors on these cell lines were first evaluated, and CD44 + MDA-MB-231 cells expressed greater amount of CD44 receptors as compared to CD44 -MCF-7 cells (Figure S9a).”
Quote in the paperSubstantial claim - Findingown data
HA-CAT@aCe6 with H2O2 presented the highest fluorescence change at 530 nm at all irradiation times.
“Considering effective generation of oxygen via the catalysis of loaded catalase on H2O2, the production of 1 O2 by HA-CAT@aCe6 with H2O2 presented the highest fluorescence change at 530 nm at all irradiation time (Figure 1h).”
Quote in the paperSubstantial claim - Findingown data
HA-CAT@aCe6 NPs induced the greatest amount of ROS as shown by the highest intensity of green fluorescence from DCF.
“The HA-CAT@aCe6 NPs were able to induce the greatest amount of ROS as shown by the highest intensity of green fluorescence from DCF.”
Quote in the paperSubstantial claim - Findingreasoning
Comparing HA@aCe6 at the same concentration under normoxic and hypoxic conditions, its cytotoxicity greatly decreased at low oxygen under hypoxic condition.
“Comparing HA@aCe6 with the same concentration at normoxic and hypoxic conditions, its cytotoxicity greatly decreased at low concentration of oxygen under hypoxic condition.”
Quote in the paperSubstantial claim - Findingown data
Flow cytometry showed greater uptake of HA-CAT@aCe6 with longer incubation time by higher mean fluorescence intensity.
“Flow cytometric results also exhibited (Figure 2a) greater uptake of HA-CAT@aCe6 with longer incubation time by having higher mean fluorescence intensity (MFI).”
Quote in the paperNot a substantial claim - Findingown data
With increasing amount of free HA preincubated, uptake of HA-CAT@aCe6 by both normoxic and hypoxic cells decreased.
“Indeed, with an increasing amount of free HA preincubated, the uptake of HA-CAT@aCe6 by both normoxic and hypoxic cells decreased”
Quote in the paperSubstantial claim - Findingown data
When incubated with aCe6, HA@aCe6, and HA-CAT@aCe6 NPs at concentrations up to 4.3 μM aCe6 in the dark, little cytotoxicity was observed, with high cell viability over 90% in normoxic cells.
“When incubated with aCe6, HA@aCe6 and HA-CAT@aCe6 NPs at different concentrations (concentration of aCe6 was as high as 4.3 µM) in the dark, a little cytotoxicity was observed, showing high cell viability of over 90% in normoxic cells.”
Quote in the paperSubstantial claim - Findingown data
HA-CAT and HA-CAT@aCe6 showed a steady increase in O2 concentration over time.
“HA-CAT and HA-CAT@aCe6 showed a steady increase in the O2 concentration upon time.”
Quote in the paperSubstantial claim - Findingown data
When only H2O2 was present in the SOSG assay, no fluorescence was observed.
“When only H2O2 was present in the solution, no fluorescence was observed.”
Quote in the paperSubstantial claim - Findingown data
HA-CAT and HA-CAT@aCe6 NPs produced significantly higher amounts of O2 when incubated with H2O2.
“On the other hand, HA-CAT and HA-CAT@aCe6 NPs produced significantly higher amounts of O2 when incubated with H2O2.”
Quote in the paperSubstantial claim - Findingown data
Free catalase activity quickly decreased to near zero within 2 h after incubation with proteinase K.
“As shown in Figure 1i, the activity of free catalase quickly decreased to near zero within 2 h after the incubation with proteinase K.”
Quote in the paperSubstantial claim - Findingown data
No major organ damage was observed in heart, liver, spleen, lung, or kidney of healthy nude mice injected with HA-CAT@aCe6 NPs.
“No major organ damage was observed (Figure S15), indicating good biocompatibility of HA-CAT@aCe6.”
Quote in the paperSubstantial claim - Findingown data
All systems administered did not show any major systemic toxicity as the weights of the mice maintained at a healthy level.
“In general, all the systems administrated did not show any major systemic toxicity as the weights of the mice all maintained at a healthy level (Figure 4b).”
Quote in the paperSubstantial claim - Findingreasoning
HA-CAT@aCe6 at the same concentration under hypoxic condition still displayed high cell killing efficacy.
“On the contrary, HA-CAT@aCe6 at the same concentration under hypoxic condition still displayed high cell killing efficacy.”
- Also stated in: § Abstract · plain
“As a result of the catalase capability in relieving hypoxia, HA-CAT@aCe6 also exhibited high cellular cytotoxicity under hypoxia condition.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
The encapsulated catalase was able to decompose endogenous H2O2 to generate O2 in situ for relieving hypoxia in cells incubated under hypoxia conditions.
“The encapsulated catalase was able to decompose the endogenous H2O2 to generate O2 in situ for relieving hypoxia in cells incubated under hypoxia conditions.”
Quote in the paperSubstantial claim - Findingown data
At the end of day 14, group V had the lowest tumor mass, followed by groups IV, III, II, and I.
“Group V had the lowest tumor mass, followed by groups IV, III, II and I (Figure 4c).”
Quote in the paperSubstantial claim - Findingreasoning
Irradiation of light did not result in inhibition of tumor growth in the free Ce6 group on account of non-accumulation of free Ce6 at the tumor site.
“On account of the non-accumulation of free Ce6 at tumor site, the irradiation of light did not result in the inhibition of tumor growth.”
Quote in the paperSubstantial claim - Findingown data
At 2 h, tumors of all treated mice showed similar fluorescence intensity.
“At 2 h, the tumors of all treated mice showed similar fluorescence intensity.”
Quote in the paperNot a substantial claim - Findingown data
Tumors treated with HA-CAT@aCe6 NPs showed obviously alleviated hypoxia compared to untreated tumors, as indicated by less intense fluorescence by HIF-1α and CD31.
“The tumors treated with HA-CAT@aCe6 NPs showed obviously alleviated hypoxia as compared to those without the treatment, as indicated by less intense fluorescence by HIF-1α and CD31.”
Quote in the paperSubstantial claim - Findingown data
HA-CAT@aCe6 NPs in the dark showed little therapeutic efficacy.
“HA-CAT@aCe6 NPs in the dark also showed little therapeutic efficacy.”
Quote in the paperSubstantial claim - Findingown data
After 24 h, ex vivo imaging showed tumors had the highest brightness, translating to the highest accumulation of HA-CAT@aCe6 NPs in tumors.
“The tumors were found to show the highest brightness, translating to the highest accumulation of HA-CAT@aCe6 NPs in tumors (Figure 3d).”
- Also stated in: § Abstract · plain
“In vivo experiments revealed selective tumor accumulation of HA-CAT@aCe6 in MDA-MB-231 tumor bearing nude mice.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingreasoning
At the same concentration of photosensitizer in both HA@aCe6 and HA-CAT@aCe6 NPs with light irradiation, cytotoxicity of HA-CAT@aCe6 NPs was greater than that of HA@aCe6.
“At the same concentration of the photosensitizer in both HA@aCe6 and HA-CAT@aCe6 NPs with light irradiation, the cytotoxicity of HA-CAT@aCe6 NPs was greater than that of HA@aCe6.”
Quote in the paperSubstantial claim - Findingown data
Tumors in group V were the smallest among all tumors.
“The tumors in group V were the smallest among all the tumors (Figure 4d).”
Quote in the paperSubstantial claim - Findingown data
HA-CAT@aCe6 NPs were successfully developed.
“In conclusion, we have successfully developed HA-CAT@aCe6 NPs capable of targeting CD44 overexpressed cancer cells and tumors as well as reducing the hypoxia to ensure high efficacy of PDT in vitro and in vivo.”
Quote in the paperSubstantial claim - Findingnone given
The method of catalase conjugation is feasible in protecting catalase from the action of proteinase K.
“This method of catalase conjugation is feasible in protecting the catalase from the action of proteinase K.”
Quote in the paperSubstantial claim - Findingreasoning
The loaded catalase was able to efficiently catalyze H2O2 to generate additional O2 toward the production of ROS for PDT.
“Thus, the loaded catalase was able to efficiently catalyze H2O2 to generate additional O2 toward the production of ROS for PDT.”
Quote in the paperSubstantial claim - Findingnone given
The protein stability of catalase was greatly enhanced through conjugation with HA polymer.
“The protein stability was greatly enhanced through the conjugation with HA polymer.”
Quote in the paperSubstantial claim - Premisecitation
Hypoxia arises in many solid tumors, particularly in regions far from the tumor blood vessels.
“Hypoxia, a term used to describe the lack of oxygen, 12 arises in many solid tumors, particularly in regions that are far from the tumor blood vessels.13”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Catalase can catalyze H2O2 to O2 for relieving hypoxia in solid tumor.
“Catalase could catalyze H2O2 to 3 O2 for relieving hypoxia in solid tumor.26”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [26] source
Not checked in the free run.
- Premisecitation
Excessive reactive oxygen species such as H2O2 are produced in cancer cells.
“It has been shown that excessive reactive oxygen species (ROS) such as H2O2 are produced in cancer cells.25”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [25] Szatrowski T. P., 1991, Cancer Res.
Not checked in the free run.
- Premisereasoning
PDT as a treatment approach shows low efficacy on account of hypoxia.
“PDT as a treatment approach also shows low efficacy on account of the hypoxia.”
Quote in the paperSubstantial claim - Premisecitation
HA is known to target overly expressed CD44 receptors in several tumors including MDA-MB-231 human breast cancer and A549 lung cancer.
“HA is known to target the overly expressed CD44 receptors in several tumors including MDA-MB-231 human breast cancer 41 and A549 lung cancer.42,43”
Quote in the paperSubstantial claim0 of 3 sources checked - Premisecitation
High molecular weight PEGylation has the disadvantage of poor biodegradability.
“However, high molecular weight PEGylation has its disadvantage of poor biodegradability.36”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [36] source
Not checked in the free run.
- Interpretationown data
The increase in size and reduction in zeta potential from highly negatively charged HA-CAT demonstrated successful conjugation of HA-CD with catalase.
“The increase in size and reduction in zeta potential from highly negatively charged HA-CAT demonstrated the successful conjugation of HA-CD with catalase (Figure 1c,d).”
Quote in the paperSubstantial claim - Interpretationreasoning
Upon light irradiation, aCe6 in HA-CAT@aCe6 produces 1O2 for PDT, even in hypoxic tumor.
“Upon light irradiation, aCe6 in HA-CAT@aCe6 produces 1 O2 for PDT, even in hypoxic tumor.”
Quote in the paperSubstantial claim - Interpretationown data
The HA component in HA-CAT@aCe6 provides targeting property, enabling specific accumulation to CD44 receptor-overexpressed cancer cells.
“confirming that the HA component in HA-CAT@aCe6 provides targeting property, enabling specific accumulation to CD44 receptor-overexpressed cancer cells (Figure 2b).”
Quote in the paperSubstantial claim - Interpretationreasoning
The decreased cytotoxicity of HA@aCe6 under hypoxia is because the oxygen required for generation of singlet oxygen to kill cancer cells was lower, impeding the therapeutic efficacy of the photosensitizer in HA@aCe6.
“This is because the oxygen required for the generation of singlet oxygen to kill cancer cells was lower under hypoxic condition, thus impeding the therapeutic efficacy of the photosensitizer in HA@aCe6.”
Quote in the paperSubstantial claim - Interpretationreasoning
Activities of HA-CAT and HA-CAT@aCe6 NPs were lower than free catalase because conjugation of HA-CD onto catalase made it less available for the catalytic reaction.
“The activities of HA-CAT and HA-CAT@aCe6 NPs were lower than that of free catalase, since the conjugation of HA-CD onto catalase made it less available for the catalytic reaction.”
Quote in the paperNot a substantial claim - Interpretationown data
The capacity of HA-CAT and HA-CAT@aCe6 NPs is high enough for catalytic production of O2 from H2O2.
“Nonetheless, the capacity of HA-CAT and HA-CAT@aCe6 NPs is high enough for catalytic production of O2 from H2O2.”
Quote in the paperSubstantial claim - Premisecitation
Both HA@aCe6 and HA-CAT@aCe6 NPs could accumulate in the tumor on account of the enhanced permeability and retention effect.
“On the other hand, both HA@aCe6 and HA-CAT@aCe6 NPs could accumulate in the tumor on account of the enhanced permeability and retention (EPR) effect.51”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [51] Matsumura Y., 1986, Cancer Res.
Not checked in the free run.
- Interpretationreasoning
The greater cytotoxicity of HA-CAT@aCe6 could be due to intrinsic H2O2 in cancer cells being catalyzed by catalase to produce more O2 for improving PDT efficacy.
“This outcome could be due to that the intrinsic H2O2 in cancer cells is catalyzed by catalase in HA-CAT@aCe6 to produce more O2 for improving the PDT efficacy.”
Quote in the paperSubstantial claim- Rests on an assumption: The intrinsic H2O2 in cancer cells is present at sufficient levels to be catalyzed by catalase in HA-CAT@aCe6 to produce enough O2 to improve PDT efficacy.
- Interpretationown data
Immunofluorescence staining results indicate HA-CAT@aCe6 NPs are capable of overcoming hypoxia associated tumors for PDT treatment.
“These immunofluorescence staining results indicate that HA-CAT@aCe6 NPs are indeed capable of overcoming hypoxia associated tumors for the PDT treatment.”
Quote in the paperSubstantial claim - Interpretationreasoning
HA-CAT@aCe6 was proven to be an efficient system for tumor-specific PDT.
“Therefore, HA-CAT@aCe6 was proven to be an efficient system for tumor-specific PDT.”
Quote in the paperSubstantial claim - Interpretationown data
HA-CAT@aCe6 NPs have good biocompatibility.
“indicating good biocompatibility of HA-CAT@aCe6.”
Quote in the paperSubstantial claim - Interpretationown data
HA-CAT@aCe6 demonstrated great potential in overcoming hypoxia for targeted PDT.
“Thus, HA-CAT@aCe6 demonstrated a great potential in overcoming hypoxia for targeted PDT.”
Quote in the paperSubstantial claim - Interpretationreasoning
The tumor-targeting ability of HA-CAT@aCe6 facilitates its internalization.
“The tumor-targeting ability of HA-CAT@aCe6 also facilitates its internalization.”
Quote in the paperNot a substantial claim - Interpretationown data
HA-CAT@aCe6 NPs ensure effective anti-tumor PDT.
“HA-CAT@aCe6 NPs displayed a great ability to target the tumor and reduce hypoxia in the tumor to ensure effective anti-tumor PDT.”
Quote in the paperSubstantial claim - Interpretationown data
HA-CAT@aCe6 NPs have a great ability to target the tumor.
“HA-CAT@aCe6 NPs displayed a great ability to target the tumor and reduce hypoxia in the tumor to ensure effective anti-tumor PDT.”
Quote in the paperSubstantial claim - Interpretationreasoning
HA-CAT@aCe6 NPs reduce hypoxia to ensure high efficacy of PDT in vitro and in vivo.
“In conclusion, we have successfully developed HA-CAT@aCe6 NPs capable of targeting CD44 overexpressed cancer cells and tumors as well as reducing the hypoxia to ensure high efficacy of PDT in vitro and in vivo.”
Quote in the paperSubstantial claim - Interpretationnone given
HA-CAT@aCe6 NPs are capable of targeting CD44 overexpressed cancer cells and tumors.
“In conclusion, we have successfully developed HA-CAT@aCe6 NPs capable of targeting CD44 overexpressed cancer cells and tumors as well as reducing the hypoxia to ensure high efficacy of PDT in vitro and in vivo.”
Quote in the paperSubstantial claim - Interpretationreasoning
Systemically administered HA-CAT@aCe6 NPs could selectively accumulate at tumor site.
“Systemically administered HA-CAT@aCe6 NPs could selectively accumulate at tumor site and attenuate the tumor hypoxia for improved PDT.”
Quote in the paperSubstantial claim - Interpretationreasoning
Systemically administered HA-CAT@aCe6 NPs attenuate tumor hypoxia for improved PDT.
“Systemically administered HA-CAT@aCe6 NPs could selectively accumulate at tumor site and attenuate the tumor hypoxia for improved PDT.”
Quote in the paperSubstantial claim - Interpretationreasoning
HA-CAT@aCe6 NPs displayed a great potential as a therapeutic agent for tumor-targeted treatment.
“Therefore, HA-CAT@aCe6 NPs displayed a great potential as a therapeutic agent for tumor-targeted treatment.”
Quote in the paperSubstantial claim - Premisecitation
Endogenous H2O2 in the human body is about 100 μM.
“Endogenous H2O2 in the human body is about 100 µM.53”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [53] source
Not checked in the free run.
- Interpretationnone given
HA-CAT@aCe6 NPs reduce hypoxia in the tumor.
“HA-CAT@aCe6 NPs displayed a great ability to target the tumor and reduce hypoxia in the tumor to ensure effective anti-tumor PDT.”
Quote in the paperNot a substantial claim
- May combine two claims. 32
- Classified as probably not a substantial claim. 7
May combine two claims.
Findingown dataH2O2 and HA@aCe6 NPs did not have a significant effect on generation of O2 in solution.
“As shown in Figure 1g, H2O2 and HA@aCe6 NPs (control group without catalase loaded) did not have a significant effect on the generation of O2 in the solution.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataHA-CD:catalase mass ratio of 3:1 was chosen for further studies because the obtained HA-CAT had a reasonable hydrodynamic diameter suitable for tumor accumulation and better retained catalase activity.
“HA-CD:catalase mass ratio of 3:1 was eventually chosen for further studies, since the obtained HA-CAT has a reasonable hydrodynamic diameter suitable for the accumulation in tumor 48 and better retained activity of catalase (Figure S5 and Table S1).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [48] source
Not checked in the free run.
May combine two claims.
Findingown dataHA-CAT NPs in water have a hydrodynamic diameter of 224.0 nm and zeta potential of -20.3 mV.
“HA-CAT NPs in water have a hydrodynamic diameter of 224.0 nm as measured by the dynamic light scattering (DLS) with zeta potential of -20.3 mV”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataFree catalase has a diameter of approximately 9.4 nm and zeta potential of -3.4 mV.
“while free catalase has a diameter of approximately 9.4 nm with zeta potential of -3.4 mV.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataHA-CAT@aCe6 NPs have a hydrodynamic diameter of 233.6 nm and zeta potential of -13.6 mV.
“HA-CAT@aCe6 NPs are slightly larger with a hydrodynamic diameter of 233.6 nm and zeta potential of -13.6 mV (Figure 1c,d).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataHA-CAT retained more than 90% of its activity after 2 h and remained high after 4 h incubation with proteinase K.
“In contrast, HA-CAT was still able to retain more than 90% of its activity after 2 h, and the activity remained high even after 4 h.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCells incubated with HA-CAT@aCe6 NPs showed less green fluorescence signal, indicating HIF-1α expression was reduced and HA-CAT@aCe6 NPs were able to alleviate hypoxia in the cells.
“Conversely, cells incubated with HA-CAT@aCe6 NPs showed less green fluorescence signal, indicating that the expression in HIF-1α was reduced and HA-CAT@aCe6 NPs were able to alleviate the hypoxia in the cells.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataUnder hypoxic condition at 1% O2, IC50 of HA@aCe6 increased to 4.8 μM, while IC50 of HA-CAT@aCe6 reduced to 0.72 μM.
“The IC50 of HA@aCe6 increased to 4.8 µM, while the IC50 of HA-CAT@aCe6 drastically reduced to 0.72 µM under hypoxic condition (Figure S13).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIC50 was 2.2 μM for HA@aCe6 and 1.4 μM for HA-CAT@aCe6 under normoxic condition.
“The half maximal inhibitory concentration (IC50) was computed to be 2.2 µM and 1.4 µM for HA@aCe6 and HA-CAT@aCe6 NPs under normoxic condition, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataHA-CAT@aCe6 or aCe6 with H2O2 under light showed obvious fluorescence increase, indicating comparable 1O2 production capability.
“Obvious fluorescence increase was measured for HA-CAT@aCe6 or aCe6 with H2O2 when irradiated under light, indicating their comparable 1 O2 production capability.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataFree catalase produced O2 at the fastest rate, reaching maximum O2 concentration at 90 s.
“Comparatively, free catalases produced O2 at the fastest rate, reaching the maximum concentration of O2 at 90 s.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataMinimal change in the size of HA-CAT@aCe6 in PBS, cell culture medium, and deionized water over three days indicated good physiological stability.
“The minimal change in the size of HA-CAT@aCe6 in different solutions (i.e., PBS, cell culture medium, and deionized water) over three days also indicated its good physiological stability (Figure S7).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn MDA-MB-231 tumor-bearing mice treated with PDT, the most severe morphological change and necrosis in tumor slices were observed in group V (HA-CAT@aCe6 NPs with light irradiation), moderate damage in group IV (HA-CAT@aCe6 NPs in the dark), and minimal damage in groups I-III.
“Based on obtained results (Figure 4e), the most severe morphological change and necrosis from tumor slices were observed in group V, while moderate damages from group IV and minimal damages from groups I-III.”
Quote in the paperSubstantial claimMay combine two claims.
Findingnone givenHA-CAT@aCe6 nanoparticles showed high colloidal stability and mono-dispersity in aqueous solution.
“HA-CAT@aCe6 nanoparticles showed high colloidal stability and mono-dispersity in aqueous solution.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataLiver showed weaker fluorescence, and other major organs such as spleen, kidney, heart, and lungs exhibited minimal fluorescence signal.
“Liver showed weaker fluorescence, and other major organs such as spleen, kidney, heart and lungs exhibited minimal fluorescence signal.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataTumor growth from group V (HA-CAT@aCe6 with light irradiation) was the most inhibited among all groups, indicating the highest anti-tumor efficacy of HA-CAT@aCe6.
“The tumor growth from group V was the most inhibited one among all groups, indicating the highest anti-tumor efficacy of HA-CAT@aCe6.”
- Also stated in: § Abstract · plain
“Significant tumor regression was observed after intravenous injection of HA-CAT@aCe6 under light irradiation in comparison to the control system without loading catalase.”
Quote in the paperSubstantial claim- Also stated in: § Abstract · plain
May combine two claims.
Findingown dataOver time, fluorescence intensity from the aCe6 group decreased, while HA@aCe6 and HA-CAT@aCe6 groups showed enhancement in fluorescence at 24 h.
“Upon time, the fluorescence intensity from aCe6 group decreased, while HA@aCe6 and HA-CAT@aCe6 groups showed an enhancement in fluorescence at 24 h time point (Figure 3a,b).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCell viability assays indicated HA-CAT@aCe6 possessed minimal cytotoxicity in the dark, while presenting high cellular toxicity under 660 nm light irradiation at normoxic condition.
“Cell viability assays indicated that HA-CAT@aCe6 possessed minimal cytotoxicity in the dark, while presenting high cellular toxicity under 660 nm light irradiation at normoxic condition.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe efficacy of PDT is restricted by the penetration depth of low wavelength light in deep-situated tumor, non-specific accumulation of photosensitizers, and the lack of endogenous oxygen in tumor.
“Despite its extensive use in cancer treatment, the efficacy of PDT is still restricted by the penetration depth of low wavelength light in deep-situated tumor, non-specific accumulation of photosensitizers and the lack of endogenous oxygen in tumor.11”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] source
Not checked in the free run.
May combine two claims.
PremisecitationDelivery of proteins such as catalase raises concerns of instability in vivo due to physiological proteases, unpredictable protein immunogenicity, and poor in vivo half-life.
“Delivery of proteins such as catalase raises a few concerns such as its instability in vivo due to the presence of numerous physiological proteases, unpredictable protein immunogenicity, and poor in vivo half-life.27,28”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationIn situ generation of oxygen using catalase is attractive because it is self-responsive to H2O2 and does not require pre-treatment with O2.
“Specifically, in situ generation of oxygen using catalase as an enzyme is attractive because it is self-responsive to hydrogen peroxide (H2O2) and does not require pre-treatment with oxygen ( 3 O2).18,19,24”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
PremisereasoningProduction of oxygen could ameliorate tumor hypoxia, leading to better PDT efficacy.
“The production of oxygen could ameliorate tumor hypoxia, leading to better PDT efficacy.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationHypoxic tumor is often resistant to drugs, limiting chemotherapy efficacy.
“Hypoxic tumor is often resistant to drugs, thus limiting the chemotherapy efficacy.15”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationMany researchers have tried to improve protein stability by encapsulating proteins within inorganic nanoparticles.
“Many researchers have tried to improve the protein stability by encapsulation them within inorganic nanoparticles (NPs).29,30”
Quote in the paperNot a substantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationUsing organic materials as nanocarriers leads to good biodistribution, easy metabolism, and better biodegradability.
“In contrast, using organic materials as nanocarriers lead to good biodistribution, easy metabolism and better biodegradablility.[31][32][33][34]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [31][32][33][34]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationPEGylation is widely used for delivery of proteins/peptides into the human body.
“PEGylation is widely used in such modification for the delivery of proteins/peptides into the human body.35”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35] source
Not checked in the free run.
Classified as probably not a substantial claim.
PremisecitationPolysaccharides such as dextran and hyaluronic acid as biodegradable polymers have been explored for modifications on proteins.
“In light of this, polysaccharides such as dextran and hyaluronic acid (HA) as biodegradable polymers 36,39 have been explored for modifications on proteins.”
Quote in the paperSubstantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
PremisecitationPolymer modification has advantages including improved stability, solubility, and pharmacokinetics.
“Numerous advantages of such polymer modification include the improved stability, solubility and pharmacokinetics.36,37”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationMany studies have reported using HA as a therapeutic carrier with covalently attached photosensitizers for targeted therapy.
“Many studies have been reported on using HA as a therapeutic carrier with covalently attached photosensitizers for targeted therapy.[44][45][46]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [44][45][46]
Not checked in the free run.
May combine two claims.
PremisecitationSupramolecular loading enables separate storage of different components and easy adjustment of the loading ratio between photosensitizer and catalase, which is tunable and predictable.
“Such supramolecular loading enables separate storage of different components and easy adjustment of the loading ratio between photosensitizer and catalase, which is tunable and predictable.47”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [47] source
Not checked in the free run.
May combine two claims.
Interpretationown dataConjugation of catalase with HA-CD polymer did improve its stability in the presence of proteinase K, which is important for tumor targeted delivery in vivo.
“Therefore, the conjugation of catalase with HA-CD polymer did improve its stability in the presence of proteinase K, which is important for tumor targeted delivery in vivo.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataHA-CAT and HA-CAT@aCe6 did not show obvious differences in O2 production from H2O2, suggesting photosensitizer loading did not affect catalase activity.
“They did not show obvious differences in the production of O2 from H2O2, suggesting that the photosensitizer loading did not affect the activity of catalase.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataUptake of HA-CAT@aCe6 by CD44+ MDA-MB-231 cells was greater, probably through CD44 receptor-mediated endocytosis.
“This result indicates that the uptake of HA-CAT@aCe6 by CD44 + MDA-MB-231 cells was greater, probably through CD44 receptormediated endocytosis.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationConjugation of enzymes to polymers is known to improve stability of enzymes due to polymer protection from proteases.
“The conjugation of enzymes to polymers was known to improve the stability of the enzymes due to the polymer protection from the proteases.37”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [37] source
Not checked in the free run.
May combine two claims.
Interpretationown dataProduction of 1O2 was enhanced in the presence of both catalase and H2O2, which could possibly promote PDT efficacy of HA-CAT@aCe6 NPs in vitro and in vivo.
“This observation indicates that the production of 1 O2 was enhanced in the presence of both catalase and H2O2, which could possibly promote the PDT efficacy of HA-CAT@aCe6 NPs in vitro and in vivo.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningHA-mediated cellular accumulation coupled with catalase-catalyzed oxygen production from endogenous H2O2 increased the amount of singlet oxygen generated, promoting cell killing efficacy of HA-CAT@aCe6 even under hypoxic condition.
“HA-mediated cellular accumulation coupled with catalase-catalyzed oxygen production 25 from endogenous H2O2 increased the amount of singlet oxygen generated, promoting the cell killing efficacy of HA-CAT@aCe6 even under hypoxic condition.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [25] Szatrowski T. P., 1991, Cancer Res.
Not checked in the free run.
May combine two claims.
PremisecitationFree Ce6 is not able to accumulate in the tumor site because it is a small molecule and could diffuse in and out of the tumor freely, resulting in being metabolized.
“Free Ce6 is not able to accumulate in the tumor site, since it is a small molecule and could diffuse in and out of the tumor freely, resulting in being metabolized.50”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [50] source
Not checked in the free run.
May combine two claims.
Interpretationown dataHA@aCe6 NPs showed moderate inhibition of tumor growth because accumulated NPs at the tumor site were not able to exhibit enough toxicity to ablate the whole tumor, leading to continual growth.
“On the other hand, HA@aCe6 NPs showed moderate inhibition of tumor growth because the accumulated NPs at the tumor site were not able to exhibit enough toxicity to ablate the whole tumor.This led to the continual growth of the tumor.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductown dataIn the in vivo therapeutic study, 25 tumor-bearing nude mice were randomly divided into five groups (five mice per group).
“For in vivo therapeutic studies, 25 tumor-bearing nude mice were randomly divided into five groups (five mice per group): I) control group with saline injection only, II) free Ce6 with light irradiation, III) HA@aCe6 NPs with light irradiation, IV) HA-CAT@aCe6 NPs in the dark, and V) HA-CAT@aCe6 NPs with light irradiation.”
Quote in the paperSubstantial claim
The paper relies on this without support.
HA is biodegradable and biocompatible with high biosafety.
“HA, a natural polysaccharide composed of alternate units of two sugar monomers i.e., glucuronic acid and Nacetylglucosamine, 40 is biodegradable and biocompatible with high biosafety.”
The paper relies on this without support.
Direct conjugation of photosensitizers onto HA results in difficulties in controlling the amount of photosensitizers delivered and prolonging the storage of light sensitive photosensitizers.
“On the other hand, such direct conjugation onto the polymer results in the difficulties in controlling the amount of photosensitizers delivered and prolonging the storage of light sensitive photosensitizers.”
The paper relies on this without support.
Inorganic nanoparticle methods often involve complicated synthesis procedures and the inorganic materials used often have issues being metabolized.
“These methods often involved complicated synthesis procedures and the inorganic materials used often have issues being metabolized.”
The paper relies on this without support.
The intrinsic H2O2 in cancer cells is present at sufficient levels to be catalyzed by catalase in HA-CAT@aCe6 to produce enough O2 to improve PDT efficacy.
“This outcome could be due to that the intrinsic H2O2 in cancer cells is catalyzed by catalase in HA-CAT@aCe6 to produce more O2 for improving the PDT efficacy.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanoparticles can generate superoxide radicals while splitting water to produce oxygen, which can promote photodynamic therapy against tumors.
“Recently, several studies have shown that nanoparticles can also generate superoxide radicals while splitting water to produce oxygen, which can promote photodynamic therapy against tumors. 443 , 444 , 445 , 446”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [445]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Treatment groups III and IV are reversed
MajorThe results identify group III as HA-CAT@aCe6 in the dark and group IV as HA@aCe6 with light, but the experimental methods assign those treatments to the opposite groups. This makes the reported group-specific tumor outcomes ambiguous.
“III: HA-CAT@aCe6 NPs in the dark, IV: HA@aCe6 with light irradiation”
“III) HA@aCe6 NPs with light irradiation, IV) HA-CAT@aCe6 NPs in the dark”
In vivo light-irradiation duration differs
MajorThe Figure 4 caption specifies 20 minutes of irradiation, but the in vivo therapeutic methods specify 30 minutes for the treated groups.
“Light (660 nm, at 50 mW cm -2 ) was irradiated for 20 min.”
“groups II, III and V received light irradiation (50 mW/cm 2 ) on the tumor for 30 min.”
Proteinase K assay identifies different nanoparticle preparations
MinorThe Figure 1i caption says the assayed preparation was HA-CAT@aCe6, while the stability-assay methods identify it as HA-CAT. These are distinct preparations in the paper.
“Relative enzymatic activity of free catalase and HA-CAT@aCe6 incubated with proteinase K over 4 h.”
“To measure and compare the stability of free catalase and HA-CAT, the Góth method was used.”
Tumor collection is stated as both day 4 and day 14
MinorThe results say tumors from all treatment groups were excised and weighed on day 14, whereas the methods say mice from each group were sacrificed on day 4 to collect their tumors. Both timelines cannot describe the same animals and tumor measurements.
“The tumors from all treatment groups were excised and weighed at the end of day 14.”
“Mice from each group were sacrificed at day 4 after the treatments to collect the tumors for evaluating the therapeutic effects.”
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,771 · see citing works
Photodynamic therapy for cancer
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1071 · Cited by 6,769 · see citing works
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · see citing works
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · see citing works
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172 · see citing works
Photodynamic therapy and anti-tumour immunity
Castaño, A. P., Mróz, P., & Hamblin, M. R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1894 · Cited by 2,685 · see citing works
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 2,504 · see citing works
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · see citing works
A simple method for determination of serum catalase activity and revision of reference range
Góth, L. (1991) · Clinica Chimica Acta · doi:10.1016/0009-8981(91)90067-m · Cited by 2,391 · see citing works
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., Pogue, B. W., & Hasan, T. G. (2010) · Chemical Reviews · doi:10.1021/cr900300p · Cited by 2,334 · see citing works
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · see citing works
Innovative Strategies for Hypoxic‐Tumor Photodynamic Therapy
Li, X., Kwon, N., Guo, T., Liu, Z., & Yoon, J. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805138 · Cited by 1,176 · see citing works
Supramolecular photosensitizers rejuvenate photodynamic therapy
Li, X., Lee, S., & Yoon, J. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00594f · Cited by 1,117 · see citing works
Hydrogen peroxide in the human body
Halliwell, B., Clement, M. V., & Long, L. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02197-9 · Cited by 1,075 · see citing works
Drug delivery by supramolecular design
Webber, M. J., & Langer, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00391a · Cited by 817 · see citing works
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 642 · see citing works
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597 · see citing works
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563 · see citing works
Tailoring nanocarriers for intracellular protein delivery
Gu, Z., Biswas, A., Zhao, M., & Tang, Y. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00227e · Cited by 543 · see citing works
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532 · see citing works
Simple Peptide‐Tuned Self‐Assembly of Photosensitizers towards Anticancer Photodynamic Therapy
Liu, K., Xing, R., Zou, Q., Ma, G., Möhwald, H., & Yan, X. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509810 · Cited by 503 · see citing works
Hyaluronan–CD44 interactions as potential targets for cancer therapy
Misra, S., Heldin, P., Hascall, V. C., Karamanos, N. K., Skandalis, S. S., Markwald, R. R., & Ghatak, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08071.x · Cited by 494 · see citing works
Li, S., Zou, Q., Li, Y., Yuan, C., Xing, R., & Yan, X. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04912 · Cited by 483 · see citing works
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410 · see citing works
Song, G., Chen, Y., Liang, C., Yi, X., Liu, J., Sun, X., Shen, S., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201602111 · Cited by 394 · see citing works
Huang, C.-C., Chia, W.-T., Chung, M.-F., Lin, K.-J., Hsiao, C.-W., Jin, C., Lim, W.-H., Chen, C.-C., & Sung, H.-W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b01784 · Cited by 372 · see citing works
Self-citationHeparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective
Götte, M., & Yip, G. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1464 · Cited by 340 · see citing works
Photodynamic therapy for prostate cancer—a review of current status and future promise
Moore, C. M., Pendsé, D. A., & Emberton, M. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1274 · Cited by 332 · see citing works
Hyaluronidase To Enhance Nanoparticle-Based Photodynamic Tumor Therapy
Gong, H., Chao, Y., Xiang, J., Han, X., Song, G., Feng, L., Liu, J., Yang, G., Chen, Q., & Liu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00068 · Cited by 322 · see citing works
Self-citation(2002) · PubMed · Cited by 296 · see citing works
Oxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor
Xu, S., Zhu, X., Zhang, C., Huang, W., Zhou, Y., & Yan, D. (2018) · Nature Communications · doi:10.1038/s41467-018-04318-1 · Cited by 292 · see citing works
Zhang, R., Song, X., Liang, C., Yi, X., Song, G., Chao, Y., Yang, Y., Yang, K., Feng, L., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.025 · Cited by 255 · see citing works
Liu, C., Wu, T., Liu, C., Chen, K., Chen, Y., Chen, G.-S., & Lin, S. (2017) · Small · doi:10.1002/smll.201700278 · Cited by 254 · see citing works
Song, G., Ji, C., Liang, C., Song, X., Yi, X., Dong, Z., Yang, K., & Liu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.020 · Cited by 238 · see citing works
Protein delivery into cells using inorganic nanoparticle–protein supramolecular assemblies
Scaletti, F., Hardie, J., Lee, Y.-W., Luther, D. C., Ray, M., & Rotello, V. M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00008e · Cited by 208 · see citing works
Hyaluronate and its derivatives for customized biomedical applications
Kim, H., Jeong, H., Han, S., Beack, S., Hwang, B. W., Shin, M., Oh, S. S., & Hahn, S. K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.029 · Cited by 193 · see citing works
Chen, Q., Chen, J., Liang, C., Feng, L., Dong, Z., Song, X., Song, G., & Liu, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.006 · Cited by 188 · see citing works
Wang, H., Chao, Y., Liu, J., Zhu, W., Wang, G., Xu, L., & Liu, Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.011 · Cited by 187 · see citing works
Review of photodynamic therapy in actinic keratosis and basal cell carcinoma
Larkö, O. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1769 · Cited by 185 · see citing works
Protein–polymer conjugation — moving beyond PEGylation
Qi, Y., & Chilkoti, A. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.08.009 · Cited by 176 · see citing works
Tham, H. P., Xu, K., Lim, W. Q., Chen, H., Zheng, M., Thng, S. T. G., Venkatraman, S. S., Xu, C., & Zhao, Y. (2018) · ACS Nano · doi:10.1021/acsnano.8b03007 · Cited by 163 · see citing works
Self-citationZhang, N., Zhao, F., Zou, Q., Li, Y., Ma, G., & Yan, X. (2016) · Small · doi:10.1002/smll.201602339 · Cited by 161 · see citing works
Mesoporous Silica Nanoparticles with Large Pores for the Encapsulation and Release of Proteins
Tu, J., Boyle, A. L., Friedrich, H., Bomans, P. H. H., Bussmann, J., Sommerdijk, N. A. J. M., Jiskoot, W., & Kros, A. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b11324 · Cited by 143 · see citing works
Yang, G., Zhang, R., Liang, C., Zhao, H., Yi, X., Shen, S., Yang, K., Cheng, L., & Liu, Z. (2017) · Small · doi:10.1002/smll.201702664 · Cited by 138 · see citing works
Self-citationCD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis
Thomas, S., Harding, M. A., Smith, S. C., Overdevest, J. B., Nitz, M. D., Frierson, H. F., Tomlins, S. A., Kristiansen, G., & Theodorescu, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3666 · Cited by 128 · see citing works
Zhu, Q., Chen, X., Xu, X., Zhang, Y., Zhang, C., & Mo, R. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707371 · Cited by 105 · see citing works
Bae, K. H., Tan, S., Yamashita, A., Ang, W. X., Gao, S. J., Wang, S., Chung, J. E., & Kurisawa, M. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.027 · Cited by 101 · see citing works
Hyaluronic acid conjugated micelles possessing CD44 targeting potential for gene delivery
Lin, L., Lee, W.-C., & Shieh, M. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.08.021 · Cited by 95 · see citing works
Wang, S., Gu, K., Guo, Z., Yan, C., Yang, T., Chen, Z., Tian, H., & Zhu, W. (2018) · Advanced Materials · doi:10.1002/adma.201805735 · Cited by 76 · see citing works
Conjugation of hyaluronan to proteins
Mero, A., Pasqualin, M., Campisi, M., Renier, D., & Pasut, G. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.11.090 · Cited by 69 · see citing works
Yang, J., Park, K., Jung, H., Kim, H., Hong, S. W., Yoon, S. K., & Hahn, S. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.088 · Cited by 55 · see citing works
Zhou, J., Xue, C., Hou, Y., Li, M., Hu, Y., Chen, Q., Li, Y., Li, K., Song, G., Cai, K., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.01.002 · Cited by 51 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Horrobin D. F., 1994, New Approaches to Cancer Treatment: Unsaturated Lipids and Photodynamic Therapy
- Beasley N. J., 2002, Cancer Res., 62, 2493
- Szatrowski T. P., 1991, Cancer Res., 51, 794
- Matsumura Y., 1986, Cancer Res., 46, 6387
Cited by
Sorted by citations
Conquering the Hypoxia Limitation for Photodynamic Therapy
Wan, Y., Fu, L., Li, C., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202103978 · Cited by 705 · see citing works
Metal–Organic Framework Derived Nanozymes in Biomedicine
Wang, D., Jana, D., & Zhao, Y. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00268 · Cited by 542 · see citing works
Self-citationOvercoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 526 · see citing works
Phototherapy in cancer treatment: strategies and challenges
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453 · see citing works
Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment
Zhang, C., Wang, X., Du, J., Gu, Z., & Zhao, Y. (2020) · Advanced Science · doi:10.1002/advs.202002797 · Cited by 404 · see citing works
Self-citationPhotodynamic therapy for hypoxic tumors: Advances and perspectives
Li, H., Zhao, S., Wu, J., Yu, L., Singh, N., Yang, K., Lan, M., Wang, P., & Kim, J. S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213888 · Cited by 372 · see citing works
Wu, T., Liu, Y., Cao, Y., & Liu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202110364 · Cited by 357 · see citing works
Xu, T., Ma, Y., Yuan, Q., Hu, H., Hu, X., Qian, Z., Rolle, J. K., Gu, Y., & Li, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b09426 · Cited by 316 · see citing works
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
Kolaříková, M., Hošíková, B., Dilenko, H., Tomankova, K. B., Válková, L., Bajgar, R., Malina, L., & Kolářová, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21935 · Cited by 291 · see citing works
Gathering brings strength: How organic aggregates boost disease phototheranostics
Qi, J., Ou, H., Liu, Q., & Ding, D. (2021) · Aggregate · doi:10.1002/agt2.25 · Cited by 284 · see citing works
An, J., Tang, S., Hong, G., Chen, W., Chen, M., Song, J., Li, Z., Peng, X., Song, F., & Zheng, W. (2022) · Nature Communications · doi:10.1038/s41467-022-29862-9 · Cited by 251 · see citing works
Nanomaterials with Supramolecular Assembly Based on AIE Luminogens for Theranostic Applications
Song, N., Zhang, Z., Liu, P., Yang, Y., Wang, L., Wang, D., & Tang, B. Z. (2020) · Advanced Materials · doi:10.1002/adma.202004208 · Cited by 229 · see citing works
Recent advances in photonanomedicines for enhanced cancer photodynamic therapy
Hu, J., Lei, Q., & Zhang, X. (2020) · Progress in Materials Science · doi:10.1016/j.pmatsci.2020.100685 · Cited by 228 · see citing works
Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia
Sahu, A., Kwon, I., & Tae, G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119578 · Cited by 218 · see citing works
Wang, J., Sun, J., Hu, W., Wang, Y., Chou, T., Zhang, B., Zhang, Q., Ren, L., & Wang, H. (2020) · Advanced Materials · doi:10.1002/adma.202001862 · Cited by 218 · see citing works
New guidelines and definitions for type I photodynamic therapy
Li, M., Xiong, J., Zhang, Y., Yu, L., Yue, L., Yoon, C., Kim, Y., Zhou, Y., Chen, X., Xu, Y., et al. (2025) · Chemical Society Reviews · doi:10.1039/d1cs01079d · Cited by 203 · see citing works
Ming, J., Zhu, T., Yang, W., Shi, Y., Huang, D., Li, J., Xiang, S., Wang, J., Chen, X., & Zheng, N. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c15211 · Cited by 190 · see citing works
Nanoparticle‐Based Photothermal Therapy for Breast Cancer Noninvasive Treatment
Xiong, Y., Rao, Y., Hu, J., Luo, Z., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202305140 · Cited by 188 · see citing works
Chlorin e6: A Promising Photosensitizer in Photo-Based Cancer Nanomedicine
Hak, A., Ali, M. S., Sankaranarayanan, S. A., Shinde, V. R., & Rengan, A. K. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00891 · Cited by 186 · see citing works
Nanoplatform-based cascade engineering for cancer therapy
Chen, J., Zhu, Y., Wu, C., & Shi, J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00607f · Cited by 184 · see citing works
Du, J., Shi, T., Long, S., Chen, P., Sun, W. C., Fan, J., & Peng, X. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213604 · Cited by 180 · see citing works
An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment
Sharifi, M., Cho, W. C. S., Ansariesfahani, A., Tarharoudi, R., Malekisarvar, H., Sari, S., Bloukh, S. H., Edis, Z., Amin, M., Gleghorn, J. P., et al. (2022) · Cancers · doi:10.3390/cancers14122868 · Cited by 180 · see citing works
Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy
Ding, C., Chen, C., Zeng, X., Chen, H., & Zhao, Y. (2022) · ACS Nano · doi:10.1021/acsnano.2c05379 · Cited by 175 · see citing works
Self-citationZhao, Y., Wang, D., Qian, T., Zhang, J., Li, Z., Gong, Q., Ren, X., & Zhao, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c03761 · Cited by 168 · see citing works
Self-citationZhou, Y., Ren, X., Hou, Z., Wang, N., Jiang, Y., & Luan, Y. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00480d · Cited by 165 · see citing works
Strategic Design of Conquering Hypoxia in Tumor for Advanced Photodynamic Therapy
Zhang, C., Hu, X., Jin, L., Lin, L., Lin, H., Yáng, Z., & Huang, W. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300530 · Cited by 158 · see citing works
Nanostructured particles assembled from natural building blocks for advanced therapies
Ju, Y., Liao, H., Richardson, J. J., Guo, J., & Caruso, F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00343g · Cited by 157 · see citing works
Recent advances and prospects of hyaluronan as a multifunctional therapeutic system
Kotla, N. G., Bonam, S. R., Rasala, S., Wankar, J., Bohara, R. A., Bayry, J., Rochev, Y. A., & Pandit, A. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.002 · Cited by 148 · see citing works
Rational Design of Nanozymes for Engineered Cascade Catalytic Cancer Therapy
Jia, X., Wang, E., & Wang, J. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00882 · Cited by 151 · see citing works
Dai, X., Huo, M., Dong, X., Hu, Y., & Liu, Y. (2022) · Advanced Materials · doi:10.1002/adma.202203534 · Cited by 140 · see citing works
Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy
Li, M., Sun, J., Zhang, W., Zhao, Y., Zhang, S., & Zhang, S. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117103 · Cited by 139 · see citing works
Self-citationYou, Y., Xu, D., Pan, X., & Ma, X. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.07.008 · Cited by 136 · see citing works
Liang, S., Sun, C., Yang, P., Ma, P., Huang, S., Cheng, Z., Yu, X., & Lin, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119850 · Cited by 131 · see citing works
Yang, Z., Du, Y., Sun, Q., Peng, Y., Wang, R., Zhou, Y. J., Wang, Y., Zhang, C., & Qi, X. (2020) · ACS Nano · doi:10.1021/acsnano.0c02249 · Cited by 130 · see citing works
Zhu, J., Xiao, T., Zhang, J., Che, H., Shi, Y., Shi, X., & van Hest, J. C. M. (2020) · ACS Nano · doi:10.1021/acsnano.0c03080 · Cited by 130 · see citing works
Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy
Wang, H., Li, J., Wang, Y., Gong, X., Xu, X., Wang, J., Li, Y., Sha, X., & Zhang, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.028 · Cited by 128 · see citing works
Ma, J., Peng, X., Zhou, Z., Yang, H., Wu, K., Fang, Z., Han, D., Fang, Y., Liu, S., Shen, Y., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210856 · Cited by 126 · see citing works
Recent advances in nanomaterial-based augmented sonodynamic therapy of cancer
Um, W., E. K., P. K., Lee, J., Kim, C. H., You, D. G., & Park, J. H. (2021) · Chemical Communications · doi:10.1039/d0cc07750j · Cited by 120 · see citing works
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works
Li, Y., Sun, P., Zhao, L., Yan, X., Ng, D. K. P., & Lo, P. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010005 · Cited by 119 · see citing works
Macrocyclic Supramolecular Assemblies Based on Hyaluronic Acid and Their Biological Applications
Liu, Z., Lin, W., & Liu, Y. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00462 · Cited by 118 · see citing works
Advances in nanomaterials for treatment of hypoxic tumor
Zou, M., Liu, W., Chen, H., Bai, X., Gao, F., Ye, J., Cheng, H. L., & Zhang, X. (2020) · National Science Review · doi:10.1093/nsr/nwaa160 · Cited by 117 · see citing works
Self-citationWei, F., Kuang, S., Rees, T. W., Liao, X., Liu, J., Luo, D., Wang, J., Zhang, X., Ji, L., & Chao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121064 · Cited by 119 · see citing works
Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer
Pucelik, B., Sułek, A., Barzowska, A., & Dąbrowski, J. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.007 · Cited by 115 · see citing works
Liu, P., Xie, X., Shi, X., Peng, Y., Ding, J., & Zhou, W. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18112 · Cited by 115 · see citing works
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115 · see citing works
Wang, D., Wu, H., Yang, G., Qian, C., Gu, L., Wang, H., Zhou, W., Liu, J., Wu, Y., Zhang, X., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c05499 · Cited by 108 · see citing works
Self-citationShen, X., Fang, K., Yie, K. H. R., Zhou, Z., Shen, Y., Wu, S., Zhu, Y., Deng, Z., Ma, P., Ma, J., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.08.031 · Cited by 102 · see citing works
Choi, J., Sun, I., Hwang, H. S., Yoon, H. Y., & Kim, K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114344 · Cited by 98 · see citing works
Versatile Nanoplatforms with enhanced Photodynamic Therapy: Designs and Applications
Yan, K. Q., Zhang, Y., Mu, C., Xu, Q., Jing, X., Wang, D., Dang, D., Meng, L., & Ma, J. (2020) · Theranostics · doi:10.7150/thno.46288 · Cited by 94 · see citing works
Zai, W., Kang, L., Dong, T., Wang, H., Yin, L., Gan, S., Lai, W., Ding, Y., Hu, Y., & Wu, J. (2021) · ACS Nano · doi:10.1021/acsnano.1c07621 · Cited by 97 · see citing works
Wang, C., Li, Y., Yang, W., Zhou, L., & Wei, S. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100601 · Cited by 93 · see citing works
Zhao, J., Duan, L., Wang, A., Fei, J., & Li, J. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1583 · Cited by 90 · see citing works
Thermo-irreversible glycol chitosan/hyaluronic acid blend hydrogel for injectable tissue engineering
Lee, E. J., Kang, E., Kang, S., & Huh, K. M. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116432 · Cited by 90 · see citing works
Wang, R., Yang, H., Khan, A. R., Yang, X., Xu, J., Ji, J., & Zhai, G. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.04.056 · Cited by 85 · see citing works
Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics
Ang, M. J. Y., Chan, S. Y., Goh, Y. Y., Luo, Z., Lau, J. W., & Liu, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113907 · Cited by 86 · see citing works
Protein-Based Nanomedicine for Therapeutic Benefits of Cancer
Zhang, Q., Zhang, J., Song, J., Liu, Y., Ren, X., & Zhao, Y. (2021) · ACS Nano · doi:10.1021/acsnano.1c00476 · Cited by 84 · see citing works
Self-citationLiu, H., Cheng, R., Dong, X., Zhu, S., Zhou, R., Yan, L., Zhang, C., Wang, Q., Gu, Z., & Zhao, Y. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b03280 · Cited by 82 · see citing works
Self-citationRecent Advances in Photodynamic Therapy for Deep-Seated Tumors with the Aid of Nanomedicine
Li, W., Yen, C.-J., Wu, B.-S., & Wong, T. (2021) · Biomedicines · doi:10.3390/biomedicines9010069 · Cited by 82 · see citing works
Jiang, Q., Qiao, B., Lin, X., Cao, J., Zhang, N., Guo, H., Liu, W., Zhu, L., Xie, X., Wan, L., et al. (2021) · Theranostics · doi:10.7150/thno.64862 · Cited by 82 · see citing works
Wen, M., Yu, N., Wu, S., Huang, M., Qiu, P., Ren, Q., Zhu, M., & Chen, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.03.009 · Cited by 81 · see citing works
Polysaccharide-based nanocarriers for efficient transvascular drug delivery
Zhang, M., Ma, H., Wang, X., Yu, B., Cong, H., & Shen, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.051 · Cited by 80 · see citing works
Strategies to Reverse Hypoxic Tumor Microenvironment for Enhanced Sonodynamic Therapy
Li, J., Yue, Z., Tang, M., Wang, W., Sun, Y., Sun, T., & Chen, C. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302028 · Cited by 81 · see citing works
Zhang, X., Chen, X., Guo, Y., Gao, G., Wang, D., Wu, Y., Liu, J., Liang, G., Zhao, Y., & Wu, F. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102059 · Cited by 78 · see citing works
Self-citationMagnetothermally Triggered Free-Radical Generation for Deep-Seated Tumor Treatment
Huang, G., Qiu, Y., Yang, F., Xie, J., Chen, X., Wang, L., & Yang, H. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00009 · Cited by 78 · see citing works
Kang, S., Gil, Y., Min, D., & Jang, H. (2020) · ACS Nano · doi:10.1021/acsnano.9b09974 · Cited by 77 · see citing works
Li, X., Pan, Y., Zhou, J., Yi, G., He, C., Zhao, Z., & Zhang, Y. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.07.092 · Cited by 75 · see citing works
Huo, M., Liu, P., Zhang, L., Wei, C., Wang, L., Chen, Y., & Shi, J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202010196 · Cited by 73 · see citing works
Xing, Y., Li, J., Wang, L., Zhu, Z., Yan, J., Liu, Y., & Liu, Q. (2025) · Advanced Materials · doi:10.1002/adma.202417942 · Cited by 73 · see citing works
Hu, D., Pan, M., Yu, Y., Sun, A., Shi, K., Qu, Y., & Qian, Z. (2020) · Open Research (University of Surrey) · doi:10.1002/viw2.6 · Cited by 72 · see citing works
Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going?
Wang, Y., Wang, H., Zhou, L., Lü, J., Jiang, B., Liu, C., & Guo, J. (2020) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.101876 · Cited by 71 · see citing works
Yuan, C.-S., Deng, Z., Qin, D., Mu, Y., Chen, X., & Liu, Y. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.02.030 · Cited by 71 · see citing works
Reactive oxygen species-upregulating nanomedicines towards enhanced cancer therapy
Ding, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., & He, B. (2022) · Biomaterials Science · doi:10.1039/d2bm01833k · Cited by 71 · see citing works
Jia, W., Wu, Y., Xie, Y., Yu, M., & Chen, Y. (2025) · Advanced Materials · doi:10.1002/adma.202413603 · Cited by 74 · see citing works
Acid-Triggered Nanoexpansion Polymeric Micelles for Enhanced Photodynamic Therapy
Zhong, S., Chen, C., Yang, G., Zhu, Y., Cao, H., Xu, B., Luo, Y., Gao, Y., & Zhang, W. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b12620 · Cited by 70 · see citing works
Self-citationAdvanced nanotechnology for hypoxia-associated antitumor therapy
Zhao, L., Fu, C., Tan, L., Li, T., Zhong, H., & Meng, X. (2020) · Nanoscale · doi:10.1039/c9nr09071a · Cited by 69 · see citing works
Zhou, R., Ohulchanskyy, T. Y., Xu, H., Ziniuk, R., & Qu, J. (2021) · Small · doi:10.1002/smll.202103569 · Cited by 68 · see citing works
Optical diagnostic imaging and therapy for thyroid cancer
Shao, C., Li, Z., Zhang, C., Zhang, W., He, R., Xu, J., & Cai, Y. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100441 · Cited by 68 · see citing works
Protein‐Based Artificial Nanosystems in Cancer Therapy
Zhang, N., Mei, K., Guan, P., Hu, X., & Zhao, Y. (2020) · Small · doi:10.1002/smll.201907256 · Cited by 68 · see citing works
Self-citationNanomaterials for cascade promoted catalytic cancer therapy
Tong, Z., Gao, Y., Huang, Y., Wang, W., & Mao, Z. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200133 · Cited by 65 · see citing works
He, H., Du, L., Xue, H., Wu, J., & Shuai, X. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.07.003 · Cited by 65 · see citing works
Li, B., Zhou, Q., Wang, H., Zha, Y., Zheng, P., Yang, T., Ma, D., Qiu, L., Xu, X., Hu, Y., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.126364 · Cited by 63 · see citing works
Xu, F., Wang, M., Dotse, E., Chow, K. T., & Lo, P. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202404561 · Cited by 63 · see citing works
Pu, Y., Zhou, B., Xiang, H., Wu, W., Yin, H., Yue, W., Yin, Y., Li, H., Chen, Y., & Xu, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120329 · Cited by 62 · see citing works
Niu, X., Liu, Y., Li, X., Wang, W., & Yuan, Z. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202006883 · Cited by 62 · see citing works
Dai, X., Dong, X., Liu, Z., Liu, G., & Liu, Y. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c01547 · Cited by 61 · see citing works
Rational design of ICD-inducing nanoparticles for cancer immunotherapy
Zhang, Z., Pan, Z., Li, Q., Huang, Q., Shi, L., & Liu, Y. (2024) · Science Advances · doi:10.1126/sciadv.adk0716 · Cited by 61 · see citing works
Liang, C., Zhang, X., Yang, M., Wang, W., Chen, P., & Dong, X. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00259 · Cited by 60 · see citing works
Mitochondria Targeted O2 Economizer to Alleviate Tumor Hypoxia for Enhanced Photodynamic Therapy
Yuan, P., Deng, F., Liu, Y., Zheng, R., Rao, X., Qiu, X., Zhang, D., Yu, X., Cheng, H. B., & Li, S. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100198 · Cited by 59 · see citing works
Yao, Y., Li, P., He, J., Wang, D., Hu, J., & Yang, X. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c05669 · Cited by 59 · see citing works
Yang, B., Dai, Z., Zhang, G., Hu, Z., Yao, X., Wang, S., Liu, Q., & Zheng, X. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901634 · Cited by 58 · see citing works
Yu, X., Zhang, Y., Yang, X., Huang, Z., Zhang, T., Yang, L., Meng, W., Liu, X., Gong, P., Forni, A., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101477 · Cited by 58 · see citing works
Zhong, W. H., Pang, L., Feng, H., Dong, H., Wang, S., Cong, H., Shen, Y., & Yu, B. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116204 · Cited by 57 · see citing works
Liu, J., Zhao, X. H., Nie, W., Yang, Y., Wu, C., Liu, W., Zhang, K., Zhang, Z., & Shi, J. (2020) · Theranostics · doi:10.7150/thno.50028 · Cited by 57 · see citing works
The role of bacteria and its derived biomaterials in cancer radiotherapy
Zhang, Y., Huang, R., Jiang, Y., Shen, W., Pei, H., Wang, G., Pei, P., & Yang, K. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.013 · Cited by 57 · see citing works
Gao, X., Feng, J., Song, S., Liu, K., Du, K., Zhou, Y., Lv, K., & Zhang, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101433 · Cited by 56 · see citing works
Chen, Z.-J., Zhang, F., Zhang, H.-B., Cheng, L., Chen, K., Shen, J., Qi, J., Deng, L., He, C., Santos, H., et al. (2021) · Advancement of science · doi:10.1002/advs.202004793 · Cited by 56 · see citing works
Gas-assisted phototherapy for cancer treatment
Zhou, J., Cao, C., Zhang, X., Zhang, X., Li, J., Deng, H., & Wang, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.015 · Cited by 55 · see citing works
Wang, J., Liu, M., Wang, J., Li, Z., Feng, Z., Xu, M., Wang, H., Li, H., Li, Z., Yu, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.002 · Cited by 55 · see citing works
Zhang, Z., Wang, R., Luo, R., Zhu, J., Huang, X., Liu, W., Liu, F., Feng, F., & Qu, W. (2021) · ACS Nano · doi:10.1021/acsnano.0c10916 · Cited by 54 · see citing works
- Authors
- Phua, S. Z. F., Yang, G., Lim, W. Q., Verma, A., Chen, H., Thanabalu, T., & Zhao, Y.
- Affiliations
- Nanyang Technological University (SG)
- Corresponding author
- Zhao, Yanli
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-04-09
- Volume
- 13
- Issue
- 4
- Pages
- 4742-4751
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2937420078
- Semantic Scholar
- e5cf6d32149402fe313dbf9698251265bd729de4
- Cited by
- 375
- References
- 52
- Citations by year
- 2026: 18 · 2025: 35 · 2024: 37 · 2023: 52 · 2022: 71 · 2021: 77 · 2020: 71 · 2019: 14
- FWCI
- 42.98
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- ACS Nano (publishedVersion)
- PubMed (publishedVersion)
- DR-NTU (Nanyang Technological University) (submittedVersion)
- Funders
- Ministry of Education - Singapore (RG114/17, RG5/16, RG11/17)
- Agency for Science, Technology and Research (A1883c0005)
- National Research Foundation Singapore (NRF-NRFI2018-03)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- photodynamic therapy, catalase, hyaluronic acid nanoparticles, chlorin e6, CD44 targeting, tumor hypoxia, hydrogen peroxide decomposition, solid tumors, tumor accumulation, MDA-MB-231 breast cancer, tumor regression
- MeSH terms
- Adamantane, Animals, Breast Neoplasms, Catalase, Chlorophyllides, Female, Humans, Hyaluronic Acid, Mice, Nude, Photochemotherapy, Porphyrins, Photosensitizing Agents, Cell Line, Tumor, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review